Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Radiation Biology
•
General Radiation Oncology
Now that we are using CBCT regularly, have there been any updates on dosimetry or second cancer risk?
Related Questions
Is there a benefit in proactively referring patients treated with pelvic radiation to see pelvic rehabilitation in the absence of any symptoms?
What are your preferred strategies to manage mild to moderate rectal ulceration causing tenesmus and discomfort after chemoradiation for rectal adenocarcinoma?
Is it safe to administer Lu 177 therapies in patients with epidural disease in the spinal canal?
How do you counsel cancer patients when they ask if they should avoid sugar?
What constraint would you use for front eye/cornea when treating with palliative intent?
How do you time PET/CT surveillance and COVID boosters?
When should vaccines be given if not received prior to the start of high dose radiation (40-50 Gy) to the spleen?
What is your approach to cancer patients who inquire about alternative or complementary treatments?
Would you hold CGRP (calcitonin gene-related peptide) monoclonal antibodies such as Eptinezumab-jjmr (Vyepti) before, during, or after lung SBRT?
Is there a time interval after which you would not offer adjuvant radiotherapy for a malignant, grade 3 meningioma?
